Satori Secures $15M to Further Preclinical Alzheimer Drugs
Pipeline comprises oral, selective modulators of gamma secretase that reduce amyloid beta 42. Satori Pharmaceuticals, a company focused on drugs for Alzheimer disease, has raised $15 million in a new financing…
Read guide →